Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
The issuer is solely responsible for the content of this announcement.
The issuer is solely responsible for the content of this announcement.